Cite
HARVARD Citation
Sasaki, K. et al. (2016). Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 122 (23), pp. 3650-3656. [Online].